Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicentre study

: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of about 2%-10% in the adult.Cyclosporin is a traditional immunosuppressive drug efficacious for treating AD, but its use is limited by several adverse event. Dupilumab is a monoclonal antibody blocking the effects of both of interleukin (IL)-4 and IL-13, pivotal cytokines in the pathogenesis of atopic diseases.For chronic conditions, such as AD, the efficacy and safety of a drug can be evaluated by drug survival (DS) analysis which gives a reflection of daily practice by evaluating the time from initiation to discontinuation of therapy.This study provides a comparative survival analysis between the only 2 drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin and dupilumab.